Sana biotechnology announces multiple preclinical data presentations to showcase its hypoimmune platform, including in type 1 diabetes, at the upcoming isscr 2022 annual meeting

New data highlighting the potential of human islet cell transplantation for type 1 diabetes will be presented new data highlighting the potential of human islet cell transplantation for type 1 diabetes will be presented
SANA Ratings Summary
SANA Quant Ranking